Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application from Zydus Lifesciences Limited for ambrisentan, granting regulatory approval of a generic version. …
-
FDA approval · 2025-04-04FDA Approved: AMBRISENTAN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Ambrisentan submitted by Aurobindo Pharma Limited under ANDA216531. This pertains to the gen…
-
FDA approval · 2025-04-02FDA Approved: TRYVIO — Supplemental Application (Idorsia Pharmaceuticals Ltd)
The FDA approved a supplemental application for TRYVIO (aprocitentan) from Idorsia Pharmaceuticals Ltd, expanding its regulatory approval.
-
FDA approval · 2025-04-02FDA Approved: OPSYNVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA page indicates a supplemental application (AP) for OPSYNVI, a fixed-dose combination of macitentan and tadalafil, submitted by Actelion …
-
FDA approval · 2025-04-02FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) filed by Actelion Pharmaceuticals US, Inc., resulting in approved chang…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
Clinical trial investigating hyperpolarized 129Xe MRI biomarkers to evaluate pulmonary arterial hypertension; status is active but not recru…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment) [Phase 2]
The RIGHT HEART III Phase 2 trial evaluating right ventricular hemodynamics and response to treatment in pulmonary arterial hypertension has…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist [Phase 1]
Phase 1 trial update reporting completion of single- and multiple-dose assessments of different formulations of a prostacyclin receptor agon…
-
CLINICAL_TRIALS withdrawal · 2025-03-30Clinical Trial Update: A Study of Macitentan in Children Below 2 Years of Age [Phase 1]
A Phase 1 pediatric trial of macitentan for pulmonary arterial hypertension in children under 2 years old has been withdrawn.
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
This retrospective chart review examines first-time macitentan (Opsumit) use in United States patients with pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH [Phase 3]
Extension of the ORCHESTRA psychometric validation study in patients with pulmonary arterial hypertension; phase 3 trial completion reported…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: A Registry for Patients Taking Uptravi
A registry study documenting patients taking Uptravi (selexipag) for pulmonary arterial hypertension has completed.
-
CLINICAL_TRIALS other · 2025-03-30Clinical Trial Update: OPsumit USers Registry
The OPSUMIT USERS Registry, sponsored by Actelion, has a completed status for macitentan (Opsumit) in pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: HRV as a Marker of Treatment Response in PAH Arterial Hypertension
A completed clinical trial evaluating whether heart rate variability can serve as a biomarker for treatment response in pulmonary arterial h…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions [NA]
This clinical trial is recruiting to investigate genetic factors linked to the development of pulmonary arterial hypertension in patients wi…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hypertension
This completed clinical trial evaluated exercise capacity, respiratory muscle strength, dyspnea, and physical activity in pediatric patients…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Repurposing Valsartan May Protect Against Pulmonary Hypertension [Phase 2]
A Phase 2 clinical trial is exploring repurposing valsartan to protect against pulmonary arterial hypertension and related right-heart condi…
-
FDA approval · 2025-03-24FDA Approved: SILDENAFIL — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for sildenafil submitted by Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
An ongoing trial is evaluating home-based clinical management of cardiac complications in systemic sclerosis, including pulmonary arterial h…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets [Phase 1]
This document provides an update on a Phase 1 multiple-dose study evaluating safety, tolerability, and pharmacokinetics of MN-08 tablets for…
-
FDA approval · 2025-03-18FDA Approved: SILDENAFIL — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for sildenafil from Aurobindo Pharma Limited. This confirms approval of a generic sildenafil product…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
A registry-based clinical trial update announcing RECRUITING for the Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry,…
-
CLINICAL_TRIALS trial_result · 2025-03-12Clinical Trial Update: Efficacy of Triple-Combination Therapy in Severe PAH-CHD
A clinical trial evaluating the efficacy of a triple-combination therapy for severe pulmonary arterial hypertension associated with congenit…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: 4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Disease [NA]
This clinical trial update notes completion of a study evaluating 4DFlow MRI in patients with pulmonary hypertension associated with congeni…
-
FDA approval · 2025-03-06FDA Approved: SILDENAFIL — Original Application (Jubilant Cadista Pharmaceuticals Inc.)
FDA approves Jubilant Cadista Pharmaceuticals' generic sildenafil (sildenafil citrate) via an original ANDA.